Evaluation of prognostic factors in male breast cancer

We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast (Edinburgh) 2001-04, Vol.10 (2), p.166-175
Hauptverfasser: Temmim, L., Luqmani, Y.A., Jarallah, M., Juma, I., Mathew, M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 175
container_issue 2
container_start_page 166
container_title Breast (Edinburgh)
container_volume 10
creator Temmim, L.
Luqmani, Y.A.
Jarallah, M.
Juma, I.
Mathew, M.
description We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinomas; 97% were grade 2 or 3. Axillary lymph node involvement was found in 69%. Estimated 5-year survival rates were 67% and 58% for overall and relapse free survival respectively. Favourable prognosis was associated with age below 50y, clinical stage I and II, small tumour size (T1, T2), low tumour grade and absence of nodal involvement or distant metastases; nodal status and grade were independent factors for relapse free survival in multivariate analysis. In 18 cases, an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89% of cases, PR in 61%, pS2 in 44%, CathD in 72%, p53 in 56%, c-erbB-2 in 50%, Ki67 and PCNA in 100% and bcl-2 in 78%. There were significant associations between several of these factors but none influenced survival. Despite the high incidence of staining of ER, our data do not support the concept of an endocrine pathway that could be usefully antagonized with antioestrogens for therapeutic benefit, as in women.
doi_str_mv 10.1054/brst.2000.0223
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71387042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960977600902236</els_id><sourcerecordid>71387042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-78bf4942361d8bfc665d60ba65593c8a981a12b10e70768dcf7580c610f88d3c3</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoiWwMiJPbAnnOLGdEVXlQ6rEArPlOA4ySuJiO5X49zhqJSamu-G59-4ehG4JFATq6qH1IRYlABRQlvQMrUlNy5yCgHO0hoZB3nDOVugqhK9ENZSJS7QiVcPqWsAase1BDbOK1k3Y9Xjv3efkQrQa90pH5wO2Ex7VYHDrjQoRazVp46_RRa-GYG5ONUMfT9v3zUu-e3t-3Tzuck0FxJyLtq-aqqSMdKnVjNUdg1al5Q3VQjWCKFK2BAwHzkSne56u0oxAL0RHNc3Q_TE3HfY9mxDlaIM2w6Am4-YgOaGCQ1qQoeIIau9C8KaXe29H5X8kAbmYkospuZiSi6k0cHdKntvRdH_4SU0CxBEw6b-DNV4GbU16vrPe6Cg7Z__L_gW523aR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71387042</pqid></control><display><type>article</type><title>Evaluation of prognostic factors in male breast cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Temmim, L. ; Luqmani, Y.A. ; Jarallah, M. ; Juma, I. ; Mathew, M.</creator><creatorcontrib>Temmim, L. ; Luqmani, Y.A. ; Jarallah, M. ; Juma, I. ; Mathew, M.</creatorcontrib><description>We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinomas; 97% were grade 2 or 3. Axillary lymph node involvement was found in 69%. Estimated 5-year survival rates were 67% and 58% for overall and relapse free survival respectively. Favourable prognosis was associated with age below 50y, clinical stage I and II, small tumour size (T1, T2), low tumour grade and absence of nodal involvement or distant metastases; nodal status and grade were independent factors for relapse free survival in multivariate analysis. In 18 cases, an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89% of cases, PR in 61%, pS2 in 44%, CathD in 72%, p53 in 56%, c-erbB-2 in 50%, Ki67 and PCNA in 100% and bcl-2 in 78%. There were significant associations between several of these factors but none influenced survival. Despite the high incidence of staining of ER, our data do not support the concept of an endocrine pathway that could be usefully antagonized with antioestrogens for therapeutic benefit, as in women.</description><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1054/brst.2000.0223</identifier><identifier>PMID: 14965580</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><ispartof>Breast (Edinburgh), 2001-04, Vol.10 (2), p.166-175</ispartof><rights>2001 Harcourt Publishers Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-78bf4942361d8bfc665d60ba65593c8a981a12b10e70768dcf7580c610f88d3c3</citedby><cites>FETCH-LOGICAL-c380t-78bf4942361d8bfc665d60ba65593c8a981a12b10e70768dcf7580c610f88d3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0960977600902236$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14965580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temmim, L.</creatorcontrib><creatorcontrib>Luqmani, Y.A.</creatorcontrib><creatorcontrib>Jarallah, M.</creatorcontrib><creatorcontrib>Juma, I.</creatorcontrib><creatorcontrib>Mathew, M.</creatorcontrib><title>Evaluation of prognostic factors in male breast cancer</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinomas; 97% were grade 2 or 3. Axillary lymph node involvement was found in 69%. Estimated 5-year survival rates were 67% and 58% for overall and relapse free survival respectively. Favourable prognosis was associated with age below 50y, clinical stage I and II, small tumour size (T1, T2), low tumour grade and absence of nodal involvement or distant metastases; nodal status and grade were independent factors for relapse free survival in multivariate analysis. In 18 cases, an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89% of cases, PR in 61%, pS2 in 44%, CathD in 72%, p53 in 56%, c-erbB-2 in 50%, Ki67 and PCNA in 100% and bcl-2 in 78%. There were significant associations between several of these factors but none influenced survival. Despite the high incidence of staining of ER, our data do not support the concept of an endocrine pathway that could be usefully antagonized with antioestrogens for therapeutic benefit, as in women.</description><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNp1kD1PwzAQhi0EoiWwMiJPbAnnOLGdEVXlQ6rEArPlOA4ySuJiO5X49zhqJSamu-G59-4ehG4JFATq6qH1IRYlABRQlvQMrUlNy5yCgHO0hoZB3nDOVugqhK9ENZSJS7QiVcPqWsAase1BDbOK1k3Y9Xjv3efkQrQa90pH5wO2Ex7VYHDrjQoRazVp46_RRa-GYG5ONUMfT9v3zUu-e3t-3Tzuck0FxJyLtq-aqqSMdKnVjNUdg1al5Q3VQjWCKFK2BAwHzkSne56u0oxAL0RHNc3Q_TE3HfY9mxDlaIM2w6Am4-YgOaGCQ1qQoeIIau9C8KaXe29H5X8kAbmYkospuZiSi6k0cHdKntvRdH_4SU0CxBEw6b-DNV4GbU16vrPe6Cg7Z__L_gW523aR</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>Temmim, L.</creator><creator>Luqmani, Y.A.</creator><creator>Jarallah, M.</creator><creator>Juma, I.</creator><creator>Mathew, M.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Evaluation of prognostic factors in male breast cancer</title><author>Temmim, L. ; Luqmani, Y.A. ; Jarallah, M. ; Juma, I. ; Mathew, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-78bf4942361d8bfc665d60ba65593c8a981a12b10e70768dcf7580c610f88d3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temmim, L.</creatorcontrib><creatorcontrib>Luqmani, Y.A.</creatorcontrib><creatorcontrib>Jarallah, M.</creatorcontrib><creatorcontrib>Juma, I.</creatorcontrib><creatorcontrib>Mathew, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temmim, L.</au><au>Luqmani, Y.A.</au><au>Jarallah, M.</au><au>Juma, I.</au><au>Mathew, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of prognostic factors in male breast cancer</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>10</volume><issue>2</issue><spage>166</spage><epage>175</epage><pages>166-175</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><abstract>We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinomas; 97% were grade 2 or 3. Axillary lymph node involvement was found in 69%. Estimated 5-year survival rates were 67% and 58% for overall and relapse free survival respectively. Favourable prognosis was associated with age below 50y, clinical stage I and II, small tumour size (T1, T2), low tumour grade and absence of nodal involvement or distant metastases; nodal status and grade were independent factors for relapse free survival in multivariate analysis. In 18 cases, an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89% of cases, PR in 61%, pS2 in 44%, CathD in 72%, p53 in 56%, c-erbB-2 in 50%, Ki67 and PCNA in 100% and bcl-2 in 78%. There were significant associations between several of these factors but none influenced survival. Despite the high incidence of staining of ER, our data do not support the concept of an endocrine pathway that could be usefully antagonized with antioestrogens for therapeutic benefit, as in women.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>14965580</pmid><doi>10.1054/brst.2000.0223</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0960-9776
ispartof Breast (Edinburgh), 2001-04, Vol.10 (2), p.166-175
issn 0960-9776
1532-3080
language eng
recordid cdi_proquest_miscellaneous_71387042
source Elsevier ScienceDirect Journals
title Evaluation of prognostic factors in male breast cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20prognostic%20factors%20in%20male%20breast%20cancer&rft.jtitle=Breast%20(Edinburgh)&rft.au=Temmim,%20L.&rft.date=2001-04-01&rft.volume=10&rft.issue=2&rft.spage=166&rft.epage=175&rft.pages=166-175&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1054/brst.2000.0223&rft_dat=%3Cproquest_cross%3E71387042%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71387042&rft_id=info:pmid/14965580&rft_els_id=S0960977600902236&rfr_iscdi=true